GXYLT2 inhibitors are a class of chemical compounds that specifically target the enzymatic activity of glucoside xylosyltransferase 2 (GXYLT2), an enzyme involved in the post-translational modification of proteins. GXYLT2 plays a role in the addition of xylose residues to O-glucosylated serine or threonine residues within proteins, a modification that is part of the complex glycosylation pathway affecting various cellular processes. Inhibitors of GXYLT2 act by blocking this enzyme's ability to transfer xylose moieties, thereby impacting the glycosylation pattern of proteins. This alteration in glycosylation can influence protein stability, folding, and interactions within the cellular environment. The inhibition of GXYLT2 can provide insights into the biological pathways regulated by this specific glycosylation step and can be used to study the functional consequences of altered xylosylation on protein behavior.
Structurally, GXYLT2 inhibitors vary in their chemical compositions but generally contain moieties that interact with the active site of the enzyme, thereby preventing its action on substrate proteins. The binding affinity and specificity of these inhibitors depend on their structural compatibility with GXYLT2, which may include features such as aromatic rings, hydrogen bond donors/acceptors, and hydrophobic pockets that enhance the interaction with the enzyme's active site. The study of GXYLT2 inhibitors is important for understanding the detailed mechanisms of protein glycosylation and the role of GXYLT2 in cellular physiology. Additionally, these inhibitors are valuable as molecular tools in biochemical research to modulate and dissect the pathways involving protein glycosylation. Through the use of GXYLT2 inhibitors, researchers can explore the fundamental processes of protein modification and their subsequent effects on cellular functions, signaling pathways, and protein-protein interactions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $99.00 $335.00 $836.00 $2099.00 | 47 | |
DAPT is a γ-secretase inhibitor that can inhibit the Notch signaling pathway, potentially affecting processes related to GXYLT2. | ||||||
Dibenzazepine (Deshydroxy LY 411575) | 209984-56-5 | sc-207554 sc-207554A | 2 mg 5 mg | $100.00 $260.00 | 4 | |
LY411575 is another potent γ-secretase inhibitor, potentially impacting the Notch pathway and indirectly GXYLT2. | ||||||
MK-0752 | 471905-41-6 | sc-364534 sc-364534A | 10 mg 50 mg | $592.00 $1550.00 | ||
MK-0752, a γ-secretase inhibitor, might indirectly modulate Notch signaling and thus GXYLT2's role. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $430.00 $1389.00 | 1 | |
RO4929097 inhibits γ-secretase, affecting Notch signaling and potentially influencing GXYLT2. | ||||||
PF-3084014 | 1290543-63-3 | sc-507501 | 5 mg | $130.00 | ||
PF-03084014, another γ-secretase inhibitor, could indirectly affect processes where GXYLT2 is involved. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts Golgi apparatus function, which could influence the glycosylation processes involving GXYLT2. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, potentially impacting the glycosylation steps where GXYLT2 is involved. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $135.00 $246.00 $619.00 $799.00 $1796.00 | 6 | |
Swainsonine, an inhibitor of Golgi mannosidase II, might affect glycosylation processes relevant to GXYLT2's function. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $180.00 $620.00 | 10 | |
Castanospermine, an alpha-glucosidase inhibitor, could impact the glycosylation steps in which GXYLT2 operates. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
Decitabine, a DNA methyltransferase inhibitor, might indirectly affect GXYLT2 by altering gene expression. | ||||||